Efficacy and Safety in Chinese Patients with Immunoglobulin a Nephropathy (IgAN) Who Have Completed Study Nef-301

NCT05534919 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Primary Immunoglobulin a Nephropathy (IgAN)

Interventions

DRUG: Nefecon

Sponsor

Everest Medicines (Singapore) Pte. Ltd.